Abstract
An intensive third generation regimen (P-VABEC) including adriamycin, etoposide, cyclophosphamide, vincristine, bleomycin and prednisolone was administered to 43 unselected elderly patients with intermediate or high-grade non-Hodgkin's lymphomas (NHL). The median age was 67, 40 per cent were Ann Arbor stage IV, 73 per cent had 'B' symptoms, 55 per cent had bulky disease, 48 per cent had serum lactate dehydrogenase greater than 450 U/l, 85 per cent had serum thymidine-kinase greater than 4 U/l. Thirty patients were previously untreated. The complete remission (CR) rate was 74 per cent, and the partial remission (PR) rate 23 per cent, with an overall response rate of 97 per cent. The regimen was carried out on an outpatient basis in all patients. No death occurred during therapy. The Kaplan-Meier actuarial survival of all patients at 3-years is 47 per cent, and 50 per cent (16/32) of all patients who attained CR remain alive and in remission at a median of 21+ months (range 6+ to 42+). These results confirm that high remission and failure-free survival rates can be achieved also in elderly unselected patients with aggressive NHL treated with curative intent.
References
Dec 1, 1976·Cancer·M J Straus
Oct 1, 1976·Cancer·E M McKelveyT E Moon
Jan 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A M SchneiderB D Clarkson
Jan 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L LongoR I Fisher
May 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E O'ReillyJ M Connors
Jan 1, 1991·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J O Armitage
Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U TirelliS Monfardini
Jul 1, 1991·Hematological Oncology·J D TigaudB Coiffier
Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R M MeyerM D Goodyear
Nov 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L LongoR C Young
Jun 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L W KwakS J Horning
Jul 1, 1990·British Journal of Cancer·P Sonneveld, J J Michiels
Mar 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D B BoydD McDermott
Dec 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M VoseJ Mailliard
Nov 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U TirelliW P Breed
Mar 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D O DixonH E Wilson
Apr 1, 1984·Journal of the American Geriatrics Society·J O Armitage, J F Potter
Dec 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MartelliF Mandelli
Apr 8, 1993·The New England Journal of Medicine·R I FisherT P Miller
Jan 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H C SchoutenA H Goldstone
Sep 1, 1993·Leukemia & Lymphoma·F CaraccioloB Grassi
Jan 1, 1993·Leukemia & Lymphoma·J M Vose, J O Armitage
Citations
Mar 29, 2000·Critical Reviews in Oncology/hematology·S M Lichtman
Oct 8, 1999·Leukemia & Lymphoma·C CampbellN L Berinstein
Jul 21, 1998·Leukemia & Lymphoma·A De RenzoB Rotoli
Jan 1, 1997·Leukemia & Lymphoma·F CaraccioloM Petrini
Apr 7, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·A NutiE Capochiani
Apr 12, 2003·Leukemia & Lymphoma·Giulia CervettiMario Petrini
May 9, 2001·Blood·P N MainwaringD Linch